 To evaluate the comparative effectiveness of extrafine hydrofluoroalkane beclometasone EF HFA-BDP and other inhaled corticosteroid ICS therapy commonly used in the UK, specifically fluticasone FP and non-extrafine NEF BDP CFC-BDP and NEF HFA-BDP in a UK primary care asthma population of current smokers. 